Omalizumab yielded a high response rate and had an acceptable safety profile in children with chronic spontaneous urticaria (CSU), including those younger than 12 years, a meta-analysis showed.

The presence of a positive chronic urticaria index, low blood histamine content, or both low immunoglobulin (Ig) E content and low blood histamine content in patients with chronic spontaneous ...

Please provide your email address to receive an email when new articles are posted on . Both guidelines begin with antihistamines. Guidelines in the US recommend further antihistamine use before ...

The U.S. Food and Drug Administration has approved Xolair (omalizumab) to treat chronic idiopathic urticaria, a form of chronic hives, according to a news release. Xolair, co-developed and co-promoted ...

Patients with CSU have an elevated risk of anxiety and depression, necessitating comprehensive management strategies. Research is focused on identifying biomarkers and clinical characteristics to ...

That price equates to an aggregate equity value of $2.2 billion, according to GSK, who added that the upfront investment net ...

This marks the fourth FDA-approved indication for Xolair across allergic and inflammatory conditions, including moderate to severe persistent allergic asthma, chronic spontaneous urticaria (CSU) and ...

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory condition in the U.S., drugmaker Celltrion announced Monday. The ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Two weeks ago, the Food and Drug Administration approved Xolair ...